Dori Pharmaceutical: in order to further optimize the equity investment structure, it is proposed to acquire the remaining 20% stake in the holding subsidiary Jiaruokang.
Dori Pharmaceutical (301075) announced that in order to further optimize the company's equity investment structure and improve the operational efficiency of the R & D platform, the company plans to use its own funds to acquire a 20 per cent stake in Wuhan Jia Nuokang Pharmaceutical Technology Co., Ltd., a holding subsidiary of Wuhan Pharmaceutical Technology Co., Ltd. The two sides of the transaction recently signed the "Equity transfer Agreement". Upon completion of the transaction, Jianokang will become a wholly owned subsidiary of the company.
Tori Pharmaceutical (301075.SZ): plans to use 26.3 million yuan of super-raised funds for permanent replenishment
301075.SZ announced that the company held the ninth meeting of the first session of the Board of Directors and the eighth meeting of the first session of the Supervisory Committee on December 24, 2021, and examined and passed the "motion on the use of part of the over-raised funds to permanently replenish current funds", agreeing that the company should use 26.3 million yuan of over-raised funds for permanent replenishment of liquidity. The bill still needs to be submitted to the company's first interim general meeting of shareholders in 2022 for consideration and approval.
301075.SZ: it is proposed to use no more than 100 million yuan of idle self-owned funds for cash management.
301075.SZ announced that the company held the eighth meeting of the first board of directors and the seventh meeting of the first board of supervisors on December 10, 2021, and passed the "motion on the use of the company's idle self-owned funds for cash management", agreeing to ensure the liquidity and safety of the company and its subsidiaries. The company and its subsidiaries intend to use idle self-owned funds of no more than RMB 100 million yuan (including capital) for cash management, within which the funds can be used on a rolling basis, and the management period shall be valid within 12 months from the date of examination and approval by the board of directors. meanwhile
301075.SZ appoints Huang Zhichun as Deputy General Manager
Zhitong Financial APP, 301075.SZ announced that the board of directors of the company agreed to appoint Mr. Huang Zhichun as the deputy general manager of the company for a term of office from the date of examination and approval of the board of directors to the expiration of the term of office of the first board of directors.
301075.SZ and its subsidiaries plan to spare no more than 100 million yuan of their own funds for cash management.
Zhitong Financial APP News, 301075.SZ announced that the company and its subsidiaries intend to use idle self-owned funds of no more than RMB100 million (including capital) for cash management, within which the funds can be used on a rolling basis, and the management period shall be valid within 12 months from the date of deliberation and approval by the board of directors.
The registration sub-IPO sector fell, while Ningbo founder (300998.CN) fell 13.41%.
[Caihua Social News] as of 10:00 this morning, the registration sector of new shares fell. Ningbo founder (300998.CN) fell 13.41% to 46.55 yuan, C Tianyima (301178.CN) fell 12.44% to 72.68 yuan, C Jinpu (301098.CN) fell 12.15% to 35.21 yuan, C Longhua (301149.CN) fell 11.37% to 24.56 yuan, C Linuo (301188.CN) fell 10.83% to 26.02 yuan, Yum Intelligence (301083.CN) fell 10.51%.
Analysis of the daily limit of Duorui Pharmaceutical on November 15: pharmaceutical concept Hot stocks
Dori Pharmaceuticals rose by the daily limit and closed at 48.83 yuan. The stock rose by the daily limit at 13:59, but did not open the limit. The closing capital was 36.4308 million yuan, accounting for 3.73% of its current market value. In terms of capital flow data, the net inflow of main funds on the same day was 80.5192 million yuan, the net inflow of hot capital was 42.7004 million yuan, and the net outflow of retail funds was 50.82 million yuan. In the past 5 days, the capital flow is shown in the following table: this stock is a hot stock of pharmaceutical concept, which rose 1.29% on the same day. The investment logic of the unit is as follows: 1. The company is mainly engaged in the research, production and marketing of chemical preparations and their raw materials.
Evaluation: the gem index fell nearly 1%. The new energy concept took the lead in smashing the market.
November 15, the two cities in the afternoon low shock, hot door heavyweights in the direction of new energy fell significantly. Auto parts plate continued to be strong, Huguang shares recorded seven consecutive plates; registered secondary new shares remained active, Dori Pharmaceuticals, Ningbo founder and other stocks rose by the daily limit; individual stocks still rose generally, with more than 3000 shares floating red, and the trading volume in Shanghai and Shenzhen stock markets exceeded one trillion yuan for the 17th trading day in a row. The 10 new stocks on the North Stock Exchange rose sharply, triggering two temporary stops in intraday trading, with N concentric rising nearly 500%, but 71 selected layer translation stocks fell, and only 9 stocks rose. By the end of the day, the Prev index was down 0.16%, and the Shenzhen index was down.
The first performance of Dori Pharmaceutical proves that profitability is pragmatic and rational, achieving the "invisible champion" of plasma substitutes.
Tibet Duorui Pharmaceutical Co., Ltd. (stock code: 301075) released its third quarter report for 2021, the first "report card" of the company since it went public on September 29th. According to the data, the company's operating income in the first three quarters was 396 million yuan, up 19.73 percent from the same period last year; the net profit belonging to shareholders of listed companies was 49.3443 million yuan, down 18.68 percent from the same period last year; and the net profit belonging to shareholders of listed companies after deducting non-recurring profits and losses was 45.1715 million yuan, up 23.73 percent from the same period last year. Among them, the third quarter
Dori Pharmaceutical reported the growth of both revenue and deduction of non-net profit in three quarters, highlighting the hard power of the main business.
(original title: 301075.SZ Pharmaceuticals reported three quarters to highlight the growth of hard power revenue and deduction of non-net profit in its main business.) Douri Pharmaceuticals (Dowry), which just landed on the gem at the end of September, early disclosed the three-quarter report that the company's main business has outstanding anti-risk ability and hard core strength, and its operating income has increased by nearly 20%. In terms of profit, although the company's net profit index has declined, its non-net profit index, which reflects the profit level of its main business, has increased by more than 20%. The third quarterly report revealed that in the first three quarters, Duorui Pharma achieved an operating income of 396 million yuan, an increase of 19.73% over the same period last year, and a net profit of 4934.43.